Company: CERO
Filing Date: 2025-06-11
Form Type: 8-K
Source: 0001213900-25-053292
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-06-11
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events.

On
June 11, 2025, the Company issued a press release announcing the Reverse Stock Split and other related information. A copy of the press
release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

Cautionary
Note Regarding Forward Looking Statements

This
communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements
regarding the Company’s expectations about the effects of the Reverse Stock Split, including the trading of the Company’s
common stock on The Nasdaq Capital Market following the Reverse Stock Split. These statements constitute projections, forecasts and forward-looking
statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to
historical or current facts. When used in this communication, words such as “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“possible,” “potential,” “predict,” “project,” “should,” “strive,”
“would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that
a statement is not forward-looking. When the Company discusses its strategies or plans, it is making projections, forecasts or forward-looking
statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, the Company’s
management.

Actual
results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual
results to differ include, among others: outcomes of the Company’s planned clinical trials and studies may not be favorable; that
one or more of the Company’s product candidate programs will not proceed as planned for technical, scientific or commercial reasons;
availability and timing of results from preclinical studies and clinical trials; uncertainty about regulatory approval to conduct clinical
trials or to market a products; uncertainties regarding intellection property protection; and those set forth in the Company’s
filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 15, 2025 and the latest
quarterly filings, and the documents incorporated by reference therein. The risks described in the Company’s filings with the Securities
and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to